Symbol Lookup

Saturday February 06, 2016 2:04 AM ET. Data delayed 15 minutes.
3.70
-0.25 (-6.33%)
Bid/Lots
3.70/0
Ask/Lots
3.73/0
Open/Prev Close
3.96/3.95
Day Range
3.58-4.04
52-Week Range
3.50-15.24
Vol/Avg Daily Vol
127.5K/64.5K
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
  • NASDAQ
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

0 New Today
CytoSorbents to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
7:00AM ET on Thursday Feb 04, 2016 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb(R) blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CEO...

CytoSorbents Corporation Gets $325,000 Non-Dilutive Funding From New Jersey Tax Program
2:51PM ET on Monday Feb 01, 2016 by MT Newswires
02:51 PM EST, 02/01/2016 (MT Newswires) -- CytoSorbents Corporation (CTSO) shares were higher over 3% on Monday after announcing the receipt of $324,606, net of transaction costs, in non-dilutive funding as an approved participant of the Technolo...
CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
7:00AM ET on Monday Feb 01, 2016 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb(R) blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the rece...

CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference
7:00AM ET on Thursday Jan 28, 2016 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb(R) blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its...

CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs
8:00AM ET on Thursday Jan 21, 2016 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb(R) blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, today anno...

Company Information

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company utilizes blood purification to modulate inflammation for treating multiple organ failure illnesses and cardiac surgery. The Company's purification technologies are based on biocompatible, porous polymer beads that can remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's product CytoSorb is approved in the European Union as an extracorporeal cytokine filter, designed to reduce the cytokine storm that could cause inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. The Company also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. In addition, CytoSorb can be used in conditions, such as cardiac surgery, autoimmune disease flares, among others.

CONTACT INFORMATION

Headquarters7 Deerpark Dr Ste K
MONMOUTH JUNCTION, NJ, United States 08852-1921
Phone973-329-8885
Fax732-329-8650

EXECUTIVE OFFICERS

Chairman of the BoardAl Kraus
President, Chief Executive Officer, DirectorPhillip Chan
Chief Financial OfficerKathleen Bloch
Chief Operating OfficerVincent Capponi
Chief Medical OfficerRobert Bartlett

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$100.2MBeta-0.01
Revenue (TTM)$3.9MEPS$-0.73
Shares Out.25.4MBook Value$0.17
Dividend Yield0.00%P/E--
Annual Dividend Rate0.00 USDPrice/Sales (TTM)25.7
Ex-Div Date1/1/01P/Cash Flow (TTM)--
Pay Date1/1/01Operating Margin-259.83%

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample